IL‐1 blockage treatment reduce the risk and incidence rate of overall major adverse cardiovascular events (MACE), all‐cause death, acute myocardial infarction(MI), unstable angina and heart failure. The gene discussed is IL1A; the disease is acute myocardial infarction.